Performance Characteristics of a Rapid Severe Acute Respiratory Syndrome Coronavirus 2 Antigen Detection Assay at a Public Plaza Testing Site in San Francisco - PubMed (original) (raw)

. 2021 Apr 8;223(7):1139-1144.

doi: 10.1093/infdis/jiaa802.

Paul Lebel 2, Sara Sunshine 3, Jamin Liu 3, Emily Crawford 2 4, Carina Marquez 5, Luis Rubio 5, Gabriel Chamie 5, Jackie Martinez 5, James Peng 5, Douglas Black 5, Wesley Wu 2, John Pak 2, Matthew T Laurie 3, Diane Jones 6, Steve Miller 7, Jon Jacobo 8, Susana Rojas 8, Susy Rojas 8, Robert Nakamura 9, Valerie Tulier-Laiwa 8, Maya Petersen 10, Diane V Havlir 5, Joseph DeRisi 2 3

Affiliations

Performance Characteristics of a Rapid Severe Acute Respiratory Syndrome Coronavirus 2 Antigen Detection Assay at a Public Plaza Testing Site in San Francisco

Genay Pilarowski et al. J Infect Dis. 2021.

Abstract

We evaluated the performance of the Abbott BinaxNOW rapid antigen test for coronavirus disease 2019 (Binax-CoV2) to detect virus among persons, regardless of symptoms, at a public plaza site of ongoing community transmission. Titration with cultured severe acute respiratory syndrome coronavirus 2 yielded a human observable threshold between 1.6 × 104-4.3 × 104 viral RNA copies (cycle threshold [Ct], 30.3-28.8). Among 878 subjects tested, 3% (26 of 878) were positive by reverse-transcription polymerase chain reaction, of whom 15 of 26 had a Ct <30, indicating high viral load; of these, 40% (6 of 15) were asymptomatic. Using this Ct threshold (<30) for Binax-CoV2 evaluation, the sensitivity of Binax-CoV2 was 93.3% (95% confidence interval, 68.1%-99.8%) (14 of 15) and the specificity was 99.9% (99.4%-99.9%) (855 of 856).

Keywords: COVID-19; Point of Care testing; Rapid Antigen Test; SARS-CoV-2.

© The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America.

PubMed Disclaimer

Figures

Figure 1.

Figure 1.

Titration of in vitro grown severe acute respiratory syndrome coronavirus 2 and detection with Binax-CoV2 assay. Top, Normalized Binax-CoV2 sample band intensity (blue-green average) for cards loaded with a known amount of virus. Error bars represent standard deviation of sample band intensity of technical replicates. Reverse-transcription polymerase chain reaction (RT-PCR) testing was performed at the CLIAHUB consortium [10]. Corresponding RT-PCR cycle threshold (Ct) values (average of N and E gene probes) are shown in black, and the corresponding RNA copy numbers in blue. Note that Ct and genome copy number correlation varies by RT-PCR platform. Bottom, Representative card images from each data point. Abbreviation: PFUs, plaque-forming units.

Figure 2.

Figure 2.

Comparison of Binax-CoV2 test with quantitative reverse-transcription polymerase chain reaction (RT-PCR) test. A, Average viral cycle threshold (Ct) values from all 26 RT-PCR–positive individuals from the community study, plotted in ascending order. Blue circles indicate Binax-CoV2–positive samples; yellow squares, Binax-CoV2–negative samples. Open symbols represent individuals who were asymptomatic on the day of the test and filled symbols, those who reported symptoms on that day. B, Normalized sample band signal from retrospective image analysis of Binax-CoV2 cards was plotted as a function of Ct value for all available scanner images (19 of 26 RT-PCR–positive samples and a random subset of RT-PCR–negative samples). Binax-CoV2 true-positives are shown in blue and labeled TP; false-negatives, shown in yellow and labeled FN; and true-negatives, shown in red and labeled TN. C, Corresponding Binax-CoV2 card images from the data in B.

Update of

Similar articles

Cited by

References

    1. Johns Hopkins Coronavirus Resource Center. COVID-19 dashboard by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University (JHU). https://coronavirus.jhu.edu/map.html. Accessed 23 October 2020.
    1. Baker MG, Wilson N, Anglemyer A. Successful elimination of Covid-19 transmission in New Zealand. N Engl J Med 2020; 383:e56. - PMC - PubMed
    1. Esbin MN, Whitney ON, Chong S, Maurer A, Darzacq X, Tjian R. Overcoming the bottleneck to widespread testing: a rapid review of nucleic acid testing approaches for COVID-19 detection. RNA 2020; 26:771–83. - PMC - PubMed
    1. Chwe H, Quintana A, Lazer D, et al. . The state of the nation: a 50-state COVID-19 survey. Report #17: COVID-19 test result times. October 2020. http://www.kateto.net/covid19/COVID19%20CONSORTIUM%20REPORT%2017%20TESTI.... Accessed 23 October 2020.
    1. Mina MJ, Parker R, Larremore DB. Rethinking Covid-19 test sensitivity—a strategy for containment. N Engl J Med 2020; 383:e120. - PubMed

Publication types

MeSH terms

Substances

Grants and funding

LinkOut - more resources